Bayer and Hologic Collaborating to Deliver Contrast-Enhanced Mammography

15 April 2024 | Monday | News

Collaboration Includes Robust Education and Training to Support Radiologists and Imaging Specialists
Image Source : Public Domain

Image Source : Public Domain

Bayer and Hologic,announced a first-of-its-kind collaboration to deliver a coordinated solution for contrast-enhanced mammography (CEM). The two companies will showcase the solution at the annual Society of Breast Imaging Symposium from April 11-14, 2024 in Montreal, Canada.

Contrast-enhanced mammography is a sensitive and relatively low-cost breast imaging modality that can be used to support breast cancer diagnosis and help to guide treatment.1 The offering brings together Hologic’s leading mammography technologies and Bayer’s leading contrast-enhanced mammography contrast delivery system, the MEDRAD® Stellant FLEX Computed Tomography (CT) Injection System. The MEDRAD Stellant FLEX CT Injection System with Certegra® Workstation is the first and only CT injection system 510(k) cleared with an additional contrast-enhanced mammography application. By working together, Hologic and Bayer are streamlining the purchasing process for radiologists and imaging facilities, providing a seamless set-up and ongoing, supportive educational resources.

"We are thrilled to work with Hologic to increase access to this emerging breast imaging modality,” said Sven Schmidt, Head of Region Americas Radiology at Bayer. “Together we will deliver an innovative and coordinated solution for both patients and healthcare professionals alike.”


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in